ArticleCell and tissue research2026
MG132 facilitates dentin regeneration by modulating inflammation and odontoblast differentiation.
Article in Cell and tissue research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although regeneration of the dentin-pulp complex is a key goal in endodontic therapy, pulpal inflammation can impede effective tissue repair and sustained healing. Recent studies suggest that proteasome inhibitors can modulate key cellular processes involved in tissue regeneration. MG132 (carbobenzoxy-Leu-Leu-leucinal) is a reversible proteasome inhibitor used in experimental settings to study these mechanisms, although its efficacy in in vivo models of dental tissue regeneration remains unclear. In this study, we investigated the effects of MG132 in modulating inflammation and regenerating dentin using a murine pulp exposure model. Involved signaling pathways were examined using in vitro-cultivated human dental pulp stem cells (hDPSCs). MG132 was then locally administered into exposed pulp cavities. Inflammation, cellular differentiation, and hard tissue formation were assessed using histological staining, immunohistochemistry, and micro-computed tomography, respectively. Following MG132 treatment of hDPSCs, RT-qPCR revealed the elevated expression of Wnt signaling-related molecules involved in dentin formation. At day 5 of treatment, MG132 significantly reduced the expression of inflammatory markers, including myeloperoxidase, F4/80, nuclear factor kappa B, and tumor necrosis factor-alpha, indicating attenuation of early excessive inflammatory responses. In addition, treatment enhanced odontoblast differentiation and mineralization, as evidenced by the upregulated expression of Nestin, collagen type I alpha-1, transforming growth factor beta 1, runt-related transcription factor 2, osteopontin, and osteocalcin. Moreover, at 42 days, MG132-treated samples exhibited distinct dentin bridge formation.
Indexed as
Identifiers
41711959What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.